Polatuzumab Biosimilar Antibody-Drug Conjugate (CD79B) for Research

Cat No.: GMP-Bios-ab-449

Pre-Made Polatuzumab biosimilar, Whole mAb ADC, Anti-CD79B Antibody: Anti-AGM6/B29/IGB therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Polatuzumab vedotin contains a monoclonal antibody that binds to a protein called CD79B, which is found on B cells (a type of white blood cell) and some lymphoma cells. It also contains an anticancer drug, which may help kill cancer cells. Polatuzumab vedotin is a type of antibody-drug conjugate. Also called Polivy.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-ab-449-1mg 1mg 243
GMP-Bios-ab-449-10mg 10mg
GMP-Bios-ab-449-100mg 100mg
GMP-Bios-ab-449-xmg >100mg



Product Details

Products Name (INN Index) Pre-Made Polatuzumab biosimilar, Whole mAb ADC, Anti-CD79B Antibody: Anti-AGM6/B29/IGB therapeutic antibody
INN Name Polatuzumab
TargetCD79B
FormatWhole mAb ADC
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2012
Year Recommended2013
CompaniesChugai Pharmaceutical;Genentech;Roche
Conditions ApprovedDiffuse large B cell lymphoma
Conditions ActiveNon-Hodgkin's lymphoma;Follicular lymphoma
Conditions DiscontinuedChronic lymphocytic leukaemia
Development Techna



About target - CD79B

1. Protein B-cell antigen receptor complex-associated protein beta chain

2. Gene CD79B

3. Organism Homo sapiens (Human)

Function
SRequired in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Enhances phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation.